ICON Public (ICLR) Stock Price, News & Analysis

Company Overview

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.

Key Stats

• Today's Range: $200.69 to $210.05
• 50-Day Range: $187.22 to $297.72
• 52-Week Range: $183.38 to $347.72
• Volume: 789,516 shs
• Average Volume: 761,812 shs
• Market Capitalization: $17.12 billion
• P/E Ratio: 23.13
• Dividend Yield: N/A
• Price Target: $289.10
• Consensus Rating: Moderate Buy

ICON Public Stock Analysis - MarketRank™

ICON Public scored higher than 86% of companies evaluated by MarketBeat, and ranked 144th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

ICON Public has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 9 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

ICON Public has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 7.23%

Earnings Growth

Earnings for ICON Public are expected to grow by 7.23% in the coming year, from $13.42 to $14.39 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ICON Public is 23.13, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 114.00.

Price to Earnings Ratio vs. Sector

The P/E ratio of ICON Public is 23.13, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 91.34.

Price to Earnings Growth Ratio

ICON Public has a PEG Ratio of 1.57. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

ICON Public has a P/B Ratio of 1.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.62% of the float of ICON Public has been sold short.

Short Interest Ratio / Days to Cover

ICON Public has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ICON Public has recently increased by 3.91%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ICON Public does not currently pay a dividend.

Dividend Growth

ICON Public does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.62% of the float of ICON Public has been sold short.

Short Interest Ratio / Days to Cover

ICON Public has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ICON Public has recently increased by 3.91%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: 0.09

News Sentiment

ICON Public has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for ICON Public this week, compared to 3 articles on an average week.

Search Interest

Only 2 people have searched for ICLR on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added ICON Public to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ICON Public insiders have not sold or bought any company stock.

Percentage Held by Insiders

44.00% of the stock of ICON Public is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

95.61% of the stock of ICON Public is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ICLR Stock Analysis - Frequently Asked Questions

How have ICLR shares performed this year?

ICON Public's stock was trading at $283.07 at the beginning of the year. Since then, ICLR stock has decreased by 26.7% and is now trading at $207.51.
View the best growth stocks for 2024 here.

How were ICON Public's earnings last quarter?

ICON Public Limited (NASDAQ:ICLR) posted its quarterly earnings results on Wednesday, October, 23rd. The medical research company reported $3.35 earnings per share for the quarter, missing analysts' consensus estimates of $3.72 by $0.37. The firm's revenue was down 1.2% compared to the same quarter last year.

Does ICON Public have any subsidiaries?

ICON Public subsidiaries include these companies: PRA Health Sciences, MedPass International, MeDiNova Research, MolecularMD, Mapi Group, Clinical Research Management, PMG Research, and more.

Who are ICON Public's major shareholders?

Top institutional investors of ICON Public include Kornitzer Capital Management Inc. KS (0.08%), Motley Fool Wealth Management LLC (0.08%), Foyston Gordon & Payne Inc (0.05%) and Captrust Financial Advisors (0.04%).

How do I buy shares of ICON Public?

Shares of ICLR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of ICON Public own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ICON Public investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Adobe (ADBE), Novo Nordisk A/S (NVO) and Jabil (JBL).

Company Calendar

• Last Earnings: 10/23/2024
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Commercial physical research
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:ICLR
• CUSIP: N/A
• CIK: 1060955
• Web: www.iconplc.com
• Phone: (531) 291-2000
• Fax: 353-1247-6260
• Employees: 41,100
• Year Founded: 1990

Price Target and Rating

• Average Stock Price Target: $289.10
• High Stock Price Target: $350.00
• Low Stock Price Target: $225.00
• Potential Upside/Downside: +39.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.85
• Research Coverage: 13 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $8.97
• Trailing P/E Ratio: 23.13
• Forward P/E Ratio: 15.46
• P/E Growth: 1.57
• Net Income: $612.34 million
• Net Margins: 9.00%
• Pretax Margin: 9.71%
• Return on Equity: 11.91%
• Return on Assets: 6.64%

Debt

• Debt-to-Equity Ratio: 0.35
• Current Ratio: 1.34
• Quick Ratio: 1.34

Sales & Book Value

• Annual Sales: $8.31 billion
• Price / Sales: 2.06
• Cash Flow: $19.04 per share
• Price / Cash Flow: 10.90
• Book Value: $112.02 per share
• Price / Book: 1.85

Miscellaneous

• Outstanding Shares: 82,495,000
• Free Float: 46,197,000
• Market Cap: $17.12 billion
• Optionable: Optionable
• Beta: 1.21